Niki BioSolutions Inc. Common Stock (NIKI)
Stock · NASDAQ · Industrials
$2.13as of 10/16/2026
Price chart
Active signals
NIKI Signal Track Record
How signals performed across all stocks →What NIKI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 23 | -6.4% | 35% | October 9, 2026 |
| Bollinger Band Breakout | 23 | -15.3% | 26% | July 20, 2026 |
| Volume Spike | 10 | -34.7% | 10% | August 24, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -18.2% | 0% | July 30, 2026 |
| Any 20-session window (baseline) | -10.1% | 33% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NIKI
Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molec…
- Sector
- Industrials
- Industry
- Industrial Machinery/Components
- Employees
- 1
- Website
- www.aptorumgroup.com/
Fundamentals
- 1-day range
- $1.94$2.4
- Market cap
- $27.62M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-3.54
- Dividend yield
- —
- Beta
- 0.09
- Avg. volume
- 158.6K
Niki BioSolutions Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NIKINiki BioSolutions Inc. Common Stock$2.03▼ 8.56%Market cap $27.62MP/E —$2.12$12.24
- XCHXCHG Limited American Depositary Share$2.61▲ 5.04%Market cap $26.56MP/E —$1.55$43.2
- CLIRClearSign Technologies Corporation Common Stock (DE)$2.4▼ 2.04%Market cap $26.14MP/E —$2.62$102
- ZEOZeo Energy Corporation Class A Common Stock$0.255▼ 5.90%Market cap $30.17MP/E —$0.1865$2.06
- BEEMBeam Global Common Stock$0.893▼ 6.88%Market cap $23.67MP/E —$0.86$4.04
- UCARU Power Limited Class A Ordinary Shares$3.38▲ 5.12%Market cap $31.74MP/E —$3.2$438
- TRSGTungray Technologies Inc Class A Ordinary Shares$1.17▼ 2.75%Market cap $23.35MP/E 34.73$1$1.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NIKI Niki BioSolutions Inc. Common Stock | $27.62M | — | $2.03 | ▼ 8.56% | $2.12$12.24 |
| XCH XCHG Limited American Depositary Share | $26.56M | — | $2.61 | ▲ 5.04% | $1.55$43.2 |
| CLIR ClearSign Technologies Corporation Common Stock (DE) | $26.14M | — | $2.4 | ▼ 2.04% | $2.62$102 |
| ZEO Zeo Energy Corporation Class A Common Stock | $30.17M | — | $0.255 | ▼ 5.90% | $0.1865$2.06 |
| BEEM Beam Global Common Stock | $23.67M | — | $0.893 | ▼ 6.88% | $0.86$4.04 |
| UCAR U Power Limited Class A Ordinary Shares | $31.74M | — | $3.38 | ▲ 5.12% | $3.2$438 |
| TRSG Tungray Technologies Inc Class A Ordinary Shares | $23.35M | 34.73 | $1.17 | ▼ 2.75% | $1$1.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Niki BioSolutions' DiamiR Biosciences Subsidiary To Perform Apolipoprotein E Genotyping On Plasma Samples From Global Alzheimer’s Platform Foundation Bio-Hermes-002 Trial Groupbenzinga · 10/14/2026
- Niki BioSolutions Enters At The Market Offering Agreement On October 9, 2026; May Sell Common Stock Up To $1.40M Aggregate Maximum Offering PriceBenzinga · 10/9/2026
- Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor ConferenceYahoo · 9/25/2026
- Niki BioSolutions Accelerates Its Alzheimer’s Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios GenomicsYahoo · 9/14/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Niki BioSolutions to join Lytham Partners Fall 2026 Investor Conference
Niki BioSolutions announced it will participate in the Lytham Partners Fall 2026 Investor Conference. This event provides a platform for the company to update stakeholders on its progress. The stock is currently trading within its 52-week range, with recent technical indicators showing moderate momentum.
Niki BioSolutions to join Lytham Partners Fall 2026 Investor Conference. Niki BioSolutions announced it will participate in the Lytham Partners Fall 2026 Investor Conference. This event provides a platform for the company to update stakeholders on its progress. The stock is currently trading within its 52-week range, with recent technical indicators showing moderate momentum.